Surmodics FY23 Raises Revenue Guidance To $102M-$106M From $103M-$107M; FY23 Now Expects EPS Of $(2.09)-$(1.69) From $(2.54)-$(2.14)
Fiscal Year 2023 Financial Guidance
Surmodics now expects fiscal year 2023 total revenue to range from $102 million to $106 million, representing an increase of 2% to 6% compared
Barrington Research Maintains Outperform on Surmodics, Lowers Price Target to $61
Barrington Research analyst Michael Petusky maintains Surmodics (NASDAQ:SRDX) with a Outperform and lowers the price target from $70 to $61.
Dow Drops 150 Points; Crude Oil Up 1%
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 150 points on Thursday.
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Gainers
Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force.
Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low
U.S. stocks traded lower this morning, with the Dow Jones dropping around 200 points on Thursday.
Surmodics Stock Slides Following Regulatory Setback For Its SurVeil Drug-Coated Balloon
Surmodics Inc (NASDAQ:SRDX) has received a letter from the FDA related to its premarket approval (PMA) application for the SurVeil drug-coated…
Surmodics Provides Regulatory Update Related To Its FDA Premarket Approval Application For The SurVeil Drug-Coated Balloon
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has received a letter from the U.S. Food and Drug Administration